Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer

INTRODUCTION: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. The active antiviral component nirmatrelvir in Paxlovid is co-formulated with ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor. Many oral targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwar, Kaleem, Nguyen, Lee, Nagasaka, Misako, Ou, Sai-Hong Ignatius, Chan, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759297/
https://www.ncbi.nlm.nih.gov/pubmed/36568522
http://dx.doi.org/10.1016/j.jtocrr.2022.100452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759297/
https://www.ncbi.nlm.nih.gov/pubmed/36568522
http://dx.doi.org/10.1016/j.jtocrr.2022.100452

Ejemplares similares